Drugs / Huminsulin Regular
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00985712 Background | Oct 2009 → Jul 2011 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Huminsulin Regular | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00985712 ↗ |
| Route | Subcutaneous | “subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks” NCT00985712 ↗ |